Cubit Diagnostics Secures SAFE Financing for Molecular Assay Development
Cubit Diagnostics has successfully closed a SAFE financing round aimed at advancing its molecular assay development and expanding its immunoassay offerings. The funding will support achieving a design freeze for its CT/NG/TV molecular assay by Q4 2026, leading to a clinical study in 2027.
CARLSBAD, Calif.–(BUSINESS WIRE)–Cubit Diagnostics today announced it has closed its latest round of SAFE (Simple Agreement for Future Equity) financing. The proceeds will fund the company’s next phase of work, centered on locking in design freeze for its molecular CT/NG/TV assay and expanding its immunoassay program. The company is on track and anticipates achieving design freeze of its CT/NG/TV molecular assay in Q4 2026, which sets up a clinical study in the first half of 2027. On the immu